Original Report

Cyclical hypofractionated radiotherapy technique for palliative treatment of locally advanced head and neck cancer: institutional experience and review of palliative regimens


 

Background Effective palliation in patients with locally advanced head and neck cancer is important. Cyclical hypofractionated radiotherapy (Quad Shot) is a short-course palliative regimen with good patient compliance, low rates of acute toxicity, and delayed late fibrosis.

Objective To review use of the Quad Shot technique at our institution in order to quantify the palliative response in locally advanced head and neck cancer.

Methods The medical records of 70 patients with head and neck squamous cell carcinoma who had been treated with the Quad Shot technique were analyzed retrospectively (36 had been treated with intensity-modulated radiation therapy and 34 with 3-D conformal radiotherapy). They had received cyclical hypofractionated radiotherapy administrated as 14.8 Gy in 4 fractions over 2 days, twice daily, repeated every 3 weeks for a total of 3 cycles. The total prescribed dose was 44.4 Gy. Primary endpoints were improvement in pain using a verbal numeric pain rating scale (range 1-10, 10 being severe pain) and dysphagia using the Food Intake Level Scale, and the secondary endpoints included overall survival (OS), local regional recurrence-free survival (LRRFS), progression-free survival (PFS) and time to progression.

Results Pain response occurred in 61% of the patients. The mean pain scores decreased significantly from pre to post treatment (5.81 to 2.55, P = .009). The mean initial dysphagia score improved from 2.20 to 4.77 55 (P = .045). 26% of patients developed mucositis (≤ grade 2), with 9% developing grade 3-level mucositis. 12 patients had tumor recurrence. The estimated 1-year PFS was 20.7%. The median survival was 3.85 months with an estimated 1-year OS of 22.6%. Pain response (hazard ratio [HR], 2.69; 95% confidence index [CI], I.552-1.77) and completion of all 3 cycles (HR, 1.71; 95% CI, 1.003-2.907) were predictive for improved OS.

Limitations This study is a retrospective analysis.

Conclusion Quad Shot is an appropriate palliative regimen for locally advanced head and neck cancer.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Increased surveillance may explain post-Fukushima pediatric thyroid cancers
MDedge Hematology and Oncology
ASTRO: Less intense chemoradiation may be possible for HPV-related oropharyngeal cancers
MDedge Hematology and Oncology
ITC: Study provides first evidence of paclitaxel benefit for anaplastic thyroid cancer
MDedge Hematology and Oncology
Adjuvant lapatinib added no benefit against head and neck squamous cell carcinoma
MDedge Hematology and Oncology
Experimental LOXO-101 induces regression in several hard-to-treat cancers
MDedge Hematology and Oncology
Suicide rate high in patients with head and neck cancer
MDedge Hematology and Oncology
Balancing clinical and supportive care at every step of the disease continuum
MDedge Hematology and Oncology
Treatment delay linked with worse outcome for head and neck cancer
MDedge Hematology and Oncology
Oncology 2015: new therapies and new transitions toward value-based cancer care
MDedge Hematology and Oncology
Thyroid nodule: not as clear-cut as it seems
MDedge Hematology and Oncology